

Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa

Benjamin Chimukangara,¹⁻³ Ayesha B.M. Kharsany,² Richard J. Lessells,¹ Kogieleum Naidoo,² Soo-Yon Rhee,⁴ Justen Manasa,⁵ Tiago Gräf,¹ Lara Lewis,² Cherie Cawood,⁶ David Khanyile,⁶ Karidia Diallo,⁷ Kassahun A. Ayalew,⁷ Robert W. Shafer,⁴ Gillian Hunt,^{8,9} Deenan Pillay,^{10,11} Salim Karim Abdool,² and Tulio de Oliveira^{1,2}

Abstract

There is evidence of increasing levels of pretreatment HIV drug resistance (PDR) in Southern Africa. We used data from two large population-based HIV surveillance studies to estimate prevalence of PDR in KwaZulu-Natal, the province with the highest HIV prevalence in South Africa. Sanger sequencing was performed on samples obtained from a longitudinal HIV surveillance program (study A, 2013–2014) and the HIV Incidence Provincial Surveillance System (study B, 2014–2015). Sequences were included for adult HIV positive participants (age ≥ 15 years for study A, age 15–49 years for study B) with no documented prior exposure to antiretroviral therapy (ART). Overall and drug class-specific PDR was estimated using the World Health Organization 2009 surveillance drug resistance mutation (SDRM) list, and phylogenetic analysis was performed to establish evidence of drug resistance transmission linkage. A total of 1,845 sequences were analyzed (611 study A; 1,234 study B). An overall PDR prevalence of 9.2% [95% confidence interval (CI) 7.0–11.7] was observed for study A and 11.0% (95% CI 8.9–13.2) for study B. In study B, the prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) PDR exceeded 10% for sequences collected in 2014 (10.2%, 95% CI 7.5–12.9). The most prevalent SDRMs were K103NS (7.5%), M184VI (2.4%), and V106AM (1.4%). There was no evidence of large transmission chains of drug-resistant virus. High level NNRTI PDR ($>10\%$) suggests a need to modify the standard first-line ART regimen and to focus attention on improving the quality of HIV prevention, treatment, and care.

Keywords: HIV, pretreatment drug resistance, antiretroviral therapy, surveillance, molecular epidemiology, South Africa

Introduction

AFTER APPROXIMATELY TWO DECADES of combination antiretroviral therapy (ART), the global response to HIV is threatened by the development of HIV drug resistance (HIVDR).¹ Pretreatment HIV drug resistance (PDR) refers to

the presence of drug resistance in a person initiating or re-initiating ART and can therefore be a combination of transmitted and acquired drug resistance (ADR). Such resistance is considered the best indicator to guide the selection of effective first-line ART regimens.²⁻⁴ While the levels of PDR in low- and middle-income countries have been low

¹KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.

²Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.

³Department of Virology, National Health Laboratory Service, University of KwaZulu-Natal, Durban, South Africa.

⁴Department of Medicine, Stanford University, Stanford, California.

⁵Department of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.

⁶Epicentre AIDS Risk Management (Pty) Limited, Paarl, Cape Town, South Africa.

⁷Centers for Disease Control and Prevention (CDC), Pretoria, South Africa.

⁸Centre for HIV and STIs, National Institute for Communicable Diseases (NICD), Johannesburg, South Africa.

⁹Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

¹⁰Africa Health Research Institute, KwaZulu-Natal, South Africa.

¹¹Division of Infection and Immunity, University College London, London, United Kingdom.

to moderate historically, there are concerns over increasing levels, given the rapid expansion in ART access and the persistent high incidence of new HIV infections.⁵ Once PDR exceeds 10%, modeling suggests that in Africa, HIVDR could account for almost half a million new infections, and \$6.5 billion in additional ART costs between 2016 and 2030.⁶

As part of its coordinated approach to prevent, monitor, and respond to the emergence of HIVDR, the World Health Organization (WHO) recommends surveys of PDR.⁴ As more people receive ART and develop ADR, the risk of transmission of drug-resistant HIV increases.⁷ The presence of PDR can lead to inadequate virologic suppression on ART and further accumulation of drug resistance mutations,^{8,9} and as a result, the levels of PDR have to be continually monitored to ensure the effective use of ART. At this critical juncture in the global response to HIV, with scale-up of universal test-and-treat and pre-exposure prophylaxis (PrEP) for HIV prevention,¹⁰ it is important to understand the current epidemiology of PDR in high-prevalence settings.

South Africa has the largest ART program in the world, with ~3.9 million people on treatment as of August 2017.¹¹ Generally, low levels of PDR have been documented in the country,^{12,13} but there is recent evidence of higher levels, which raises concern over the continued effectiveness of first-line non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based ART regimens.^{14–16} The evidence of increasing PDR is in the context of a growing number of people with virological failure on ART and delayed switching to second-line ART, creating an expanding pool of those with ADR.¹⁷ In this article, we present estimates of PDR from two population-based studies in KwaZulu-Natal Province (KZN), South Africa.

Materials and Methods

Setting

The Africa Health Research Institute (AHRI) has conducted longitudinal population-based HIV surveillance in the uMkhanyakude District Municipality, northern KZN since 2003 (Study A, Fig. 1).¹⁸ All individuals 15 years and older in a population of ~65,000 resident members are invited to provide dried blood spot (DBS) specimens on an annual basis. For this study, viral reverse transcription polymerase chain reaction (PCR) was performed on the DBS specimens of the participants with a positive HIV enzyme-linked immunosorbent assay (ELISA) in 2013 or 2014, who had a DBS HIV RNA $\geq 10,000$ copies/mL. PCR and sequencing were also attempted on some DBS specimens with HIV RNA $< 10,000$ copies/mL, but this was not pursued as the rate of successful amplification was low. We excluded sequences obtained from participants with documented ART initiation before the date of specimen collection. Information about ART use was obtained through linkage of the population surveillance data with routine HIV program data.¹⁹ This did not include information about prior use of antiretrovirals for prevention of mother-to-child transmission (pMTCT). We estimated the date of HIV infection using the midpoint between the last negative test date and the first positive test date and estimated the duration of infection in months, by calculating the time between the estimated date of infection and the sample collection date, as described previously.¹⁴

Epicentre AIDS Risk Management, The Centre for the AIDS Programme of Research in South Africa (CAPRISA), and the United States Centers for Disease Control and Prevention (CDC) coordinate the HIV Incidence Provincial Surveillance System (HIPSS) in two subdistricts of uMgungundlovu District Municipality in central KZN (Study B, Fig. 1).^{20–22} In 2014–2015, a representative cross-sectional household survey enrolled 9,812 individuals aged 15–49 years. A multistage cluster sampling technique was used to randomly select the households and individuals included in the study, as described previously.²³ One individual was selected per household. From the 14,618 households found and occupied, 9,812 individuals were eligible and consented to participate. HIV ELISA was performed on the peripheral blood specimens of the participants,²² and sequencing was performed on the plasma specimens from participants with positive HIV serology and plasma HIV RNA $\geq 1,000$ copies/mL.²¹ For the analysis, we excluded sequences from those who self-reported any prior ART use (for treatment or pMTCT). Details on the timing of recruitment and ascertainment of ART status for the two population-based studies are provided in Supplementary Data.

Laboratory methods and data analysis

Genotypic drug resistance testing of the HIV-1 *reverse transcriptase (RT)* and *protease (PR)* genes was done on stored specimens by Sanger sequencing on an ABI 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA) using previously described methods.²⁴ Sequence quality and coverage were assessed using the Calibrated Population Resistance (CPR) tool (<http://cpr.stanford.edu/cpr.cgi>). Sequences that had quality concerns, such as stop codons, or that did not cover all possible surveillance drug resistance mutation (SDRM) positions, were excluded. We included participants with complete *RT* sequences, with or without the *PR* sequence.

PDR was determined by detecting SDRMs with the CPR tool using the WHO 2009 SDRM list.^{25,26} The results were used to estimate the levels of overall and drug class-specific resistance for each study, with the data being analyzed using STATA version 15.1 (StataCorp, College Station, TX) and SAS version 9.4 (SAS Institute, Cary, NC). The chi-square test was used to establish any difference in PDR prevalence across the years, within each study, with a Rao-Scott chi-square test being used for study B to adjust for the survey design. Logistic regression analysis was performed to explore associations between PDR and individual participant characteristics for each study (i.e., sex, age, HIV RNA, and for study A; the estimated duration of infection) and accounted for the survey sample design in study B. Where appropriate, analyses for study B were conducted by applying sampling weights and using survey procedures. The sampling weights were adjusted for nonequal probabilities of selection associated with the complex survey design and for nonresponse across age and gender categories.²⁰ The confidence intervals (CIs) were calculated using Wald confidence limits, and the Taylor series linearization method was used to estimate standard errors of proportions.

To establish evidence of SDRM transmission, we performed phylogenetic analysis to identify HIV transmission




FIG. 1. Location of the two population-based studies.

clusters. Sequences with drug resistance mutations identified in this study were aligned with a background dataset of 15,313 HIV-1 subtype *C pol* sequences. This consisted of publicly available sequences from the Los Alamos HIV Database (www.hiv.lanl.gov), isolated from Southern African countries, and sequences generated previously from the AHRI surveillance population.^{14,17,27} To avoid cluster formation due to convergent evolution under ART pressure, codon positions associated with drug resistance mutations were removed from the alignment.²⁸

A maximum likelihood (ML) phylogenetic tree was constructed using FastTree2,²⁹ and cluster support was assessed with Shimodaira–Hasegawa approximate likelihood ratio test (SH-aLRT) with 1,000 pseudo-replicates. HIV-1 transmission clusters were identified from the ML tree using the ClusterPicker software version 1.2.3,³⁰ where the definitions of a transmission cluster were set to a minimum clade support of 90 SH-aLRT and a maximum within-cluster genetic distance of 4.5%. To identify if sequences clustering together had similar SDRMs, we further submitted the full-length sequences (with all codon positions) to the CPR tool.

Ethics statement

Approval for the two studies was obtained from the Biomedical Research Ethics Committee of the University of KwaZulu-Natal (UKZN) (reference nos. BF233/09 and BF269/13), the KZN Provincial Department of Health (HRKM 08/14), and the Center for Global Health, CDC. Written informed consent for use of stored specimens was obtained from all study participants.

Results

A total of 1,845 HIV-1 sequences were included in the analysis and consisted of 611 sequences for study A, with 254 from 2013 and 357 from 2014. From study B, 1,234 sequences were included, with 737 from 2014 and 497 from 2015 (Fig. 2).

Overall, 1,841 had complete *RT* and *PR* sequences, and 4 had only the complete *RT* sequence. The characteristics of the participants included in the analysis are summarized in Table 1. The estimated prevalence of PDR was 9.2% (95% CI 7.0–11.7) for study A and 11.0% (95% CI 8.9–13.2) for study B. The estimated prevalence of NNRTI PDR was 7.5% (95% CI 5.6–9.9) for study A and 9.2% (95% CI 7.2–11.3) for study B. There was no evidence of an increase in overall PDR or NNRTI PDR across the 2 years in either study (Fig. 3). The estimated prevalence of PDR was higher for women than men in both studies: 9.9% versus 7.1% for study A [odds ratio (OR) 1.45, 95% CI 0.73–2.87] and 13.6% versus 8.3% for study B (OR 1.73, 95% CI 1.06–2.81) (Table 2 and Supplementary Fig. S1).

The prevalence of PDR peaked at 17.0% (95% CI 11.9–22.1) in women aged 25–34 years in study B (Supplementary Table S1). There was no strong evidence of an association between PDR and age or HIV RNA in either study (Table 2). In study A, the prevalence of PDR was lower in those with an estimated duration of infection ≤ 24 months than in those with estimated duration >24 months (3.0% vs. 8.6%), but the analysis was limited by small numbers with recent infection ($n=66$) (Table 2).

Of all 1,845 sequences across the two studies, 212 (11.5%) had at least one SDRM. The frequency of individual SDRMs by study year is displayed in Table 3. Overall, 182/1,845




FIG. 2. Summary of the specimens and HIV-1 sequences from the two studies in KZN, South Africa. ^aExcluded due to incomplete RT sequences. KZN, KwaZulu-Natal Province; RT, reverse transcriptase.

(10.0%) had NNRTI mutations, 59/1,845 (3.2%) had nucleoside reverse-transcriptase inhibitor (NRTI) mutations, and 23/1,841 (1.2%) had protease inhibitor (PI) mutations (Table 3). Of those with SDRMs, 162 (76.4%) had single class resistance, 48 (22.6%) dual class resistance, and 2 (1.0%) triple class resistance. The most frequently observed SDRM was the NNRTI mutation K103NS, occurring in 139

participants (7.5% of all participants or 65.6% of those with SDRMs). In 100 participants (47.2% of those with drug resistance mutations), the K103NS mutation was the only SDRM detected. The most frequently observed patterns of SDRMs are listed in Supplementary Table S2.

The most common NRTI mutation was M184VI (2.4%), and in almost all cases (43 of 44) it was detected in combination

TABLE 1. STUDY PARTICIPANTS' DEMOGRAPHIC AND CLINICAL CHARACTERISTICS

| | Total | AHRI surveillance (study A) | | HIPSS (study B) | |
|---|------------------|-----------------------------|------------------|------------------|------------------|
| | | 2013 | 2014 | 2014 | 2015 |
| Participants | 1,845 | 254 | 357 | 737 | 497 |
| Sex, female, n (%) | 1,269 (69) | 186 (73) | 269 (75) | 507 (69) | 307 (62) |
| Age, years, median (IQR) | 30 (25–39) | 30 (24–40) | 33 (26–42) | 30 (24–38) | 30 (24–36) |
| HIV RNA, log ₁₀ copies/mL, median (IQR) ^a | 4.50 (4.02–4.96) | 4.77 (4.35–5.18) | 4.70 (4.36–5.10) | 4.39 (3.80–4.87) | 4.41 (3.91–4.83) |

^aHIV RNA missing for 84 participants (77 study A, 7 study B).

AHRI, Africa Health Research Institute; HIPSS, HIV Incidence Provincial Surveillance System; IQR, interquartile range.




FIG. 3. Levels of pretreatment drug resistance (A) and NNRTI-specific pretreatment drug resistance (B). Marker line in (B) corresponds to 10% threshold for NNRTI PDR. Prevalence estimates and confidence intervals for study B were weighted to adjust for the survey design and for non-response across age and gender categories. NNRTI, non-nucleoside reverse-transcriptase inhibitor; PDR, pretreatment HIV drug resistance.

with at least one NNRTI mutation, and in half the cases (22 of 44) with other NRTI mutations. The K65R mutation associated with tenofovir (TDF) resistance was detected in 11 participants overall (0.6%), with no evidence of an increase across the 2 years in either study. Of the 23 with PI mutations, 20 had a single PI mutation. The most common PI mutation was the M46I mutation, occurring in 18 participants. Two participants with four or more PI mutations had similar patterns of PI resistance (M46I, I54V, L76V, V82A), with one participant having in addition the L90M mutation. In both cases, there was triple class resistance with NRTI mutations (M184V, L74V) and an NNRTI mutation (K103S).

From the phylogenetic analysis, we identified 25 transmission clusters with individuals harboring at least one PDR mutation in common (Supplementary Fig. S2). In total, 57 individuals were grouped in these transmission clusters, 56% (32/57) were from studies A and B, and 44% (25/57) were

South African individuals whose sequences were present in the background dataset. Individuals from studies A and B (in the transmission linkages) comprised 15% (32/212) of the sequences with any PDR mutations identified here. From the background dataset, we had information about ART exposure for 18 of the 25 individuals. Sixteen of the 18 (89%) were ART experienced and were linked to 14 ART-naive individuals with PDR (Supplementary Fig. S2). K103NS was the most common PDR mutation, observed in 72% (41/57) of individuals involved in linked transmissions.

Discussion

Surveillance of HIVDR is a key component of the public health approach to sustainable use of ART. In this analysis, we found moderate-to-high levels of PDR in two KZN districts between 2013 and 2015, at approximately the turn

TABLE 2. ASSOCIATION BETWEEN PRETREATMENT DRUG RESISTANCE AND PARTICIPANT CHARACTERISTICS

| Category | Study A | | | Study B | | |
|--------------------------------------|---------|-----------|------------------|---------|------------|------------------|
| | N | n (%) | OR (95% CI) | N | n (%) | OR (95% CI) |
| Sex | | | | | | |
| Male | 156 | 11 (7.1) | 1 | 420 | 39 (9.3) | 1 |
| Female | 455 | 45 (9.9) | 1.45 (0.73–2.87) | 814 | 117 (14.4) | 1.64 (1.12–2.41) |
| Age, years | | | | | | |
| 15–24 | 145 | 15 (10.3) | 1.28 (0.62–2.62) | 314 | 40 (12.7) | 0.88 (0.58–1.34) |
| 25–34 | 217 | 18 (8.3) | 1 | 507 | 72 (14.2) | 1 |
| 35–44 | 125 | 10 (8.0) | 0.96 (0.43–2.15) | 319 | 30 (9.4) | 0.63 (0.40–0.98) |
| 45+ | 124 | 13 (10.5) | 1.29 (0.61–2.74) | 94 | 14 (14.9) | 1.06 (0.57–1.97) |
| HIV RNA, log ₁₀ copies/mL | | | | | | |
| <4 | 51 | 4 (7.8) | 1 | 372 | 61 (16.4) | 1 |
| 4–5 | 309 | 33 (10.7) | 1.40 (0.48–4.15) | 619 | 61 (9.9) | 0.56 (0.38–0.82) |
| >5 | 174 | 14 (8.0) | 1.03 (0.32–3.27) | 236 | 33 (14.0) | 0.83 (0.52–1.31) |
| Missing | 77 | 5 (6.5) | 0.82 (0.21–3.20) | 7 | 1 (14.3) | 0.85 (0.10–7.18) |
| Duration of infection ^a | | | | | | |
| ≤24 months | 66 | 2 (3.0) | 0.33 (0.08–1.42) | — | — | — |
| >24 months | 385 | 33 (8.6) | 1 | — | — | — |
| Unknown | 160 | 21 (13.1) | 1.61 (0.90–2.88) | — | — | — |

^aFor those with a prior negative HIV ELISA in the population surveillance, estimated date of infection was calculated as midpoint between last negative HIV ELISA and first positive HIV ELISA. Estimated duration of infection was then calculated from that date of infection to the date that the sample processed for sequencing was collected. For those with only prior positive HIV ELISA tests, duration of infection was taken to be >24 months if there was a positive HIV ELISA more than 24 months before the sample date. Unknown duration of infection implies no prior negative HIV ELISA and no prior positive HIV ELISA beyond 24 months.

CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; OR, odds ratio.

of the second decade of ART rollout. The results from the AHRI longitudinal population surveillance suggest a continued trend of steadily increasing PDR since 2010.¹⁴ In the HIPSS cross-sectional survey, the level of NNRTI PDR was close to 10%, the current threshold at which the WHO recommends urgent public health action.^{2,3} The attempt to exclude people with prior ART exposure means that our findings are likely to reflect predominantly transmitted resistance. The levels of resistance documented and the phylogenetic analysis therefore suggest increasing transmission of HIVDR from people treated with ART. This raises concerns about the quality of HIV prevention, treatment, and care and should prompt consideration of appropriate public health measures to ensure the long-term sustainability of ART.

The timing of this increase in levels of PDR is consistent with other findings from sub-Saharan Africa, where PDR rose to moderate levels about 10 years into ART scale-up.^{31,32} To some extent, our findings are consistent with a nationally representative survey conducted in South Africa in 2013–2014, which estimated the prevalence of PDR at 9.0% and NNRTI PDR at 8.3% nationally.¹⁵ The two sites are similar in terms of demographics, HIV epidemiology, and HIV care cascades.^{22,33} However, there were some differences in the study populations, particularly the higher HIV RNA levels in study A due to the use of DBS samples for sequencing, as the amplification success rate reduces at lower HIV RNA levels (<10,000 copies/mL) in DBS samples.³⁴ Using DBS samples, which have a higher HIV RNA requirement for genotyping, could have resulted in an underestimation of the levels of resistance for study A, as drug-resistant viruses have a lower replicative capacity than the wild-type virus, which could result in lower HIV RNA levels, although this may depend on the specific profile of mutations.^{35,36}

Another difference between the two studies was the method used to determine prior ART use. It is possible that the self-report of ART use in the HIPSS (study B) was less reliable than linkage to health service records as a method for uncovering current or prior use of ART. Significant undisclosed ART use has been documented in other population-based surveys,^{37,38} and if people on ART were inadvertently included in the sample for this analysis, then the levels of PDR from the HIPSS (study B) may be overestimated. Given these difficulties, it is possible that future studies should include testing for antiretroviral drug levels to determine the true ART status. Although the PDR prevalence was somewhat higher in women in both studies, the difference was not as marked as that reported for a number of recent national PDR surveys.⁵ In addition, we did not observe a clear gradient in PDR across age groups, unlike a recent study in Kenya,³⁹ although it is notable that PDR levels were particularly high in young women, the group with the highest HIV incidence in these populations.²¹

The rapid expansion of ART coverage has been a considerable achievement in South Africa, having resulted in substantial gains in life expectancy.^{40,41} Routine viral load (VL) monitoring to guide ART switches has been incorporated into the treatment program since the start of ART rollout. Despite this, implementation remains inconsistent, and the results are often not appropriately acted upon.^{42–45} With the resulting delays in switching to second-line ART regimens, people spend more time being viremic and at risk of accumulating drug resistance.¹⁷ With the growing case-loads of people on first-line ART, this suggests that there will be an expanding pool of people with ADR, creating conditions for an increase in the transmission of HIVDR.⁴⁶ Our findings lend support to calls for increased focus on quality

TABLE 3. SURVEILLANCE DRUG RESISTANCE MUTATIONS DETECTED IN TWO POPULATION-BASED STUDIES IN KWAZULU-NATAL PROVINCE, SOUTH AFRICA

| | <i>AHRI surveillance (study A)</i> | | <i>HIPSS (study B)</i> | | <i>Overall n = 1,845</i> |
|---------------------------------|------------------------------------|-------------------------|-------------------------|-------------------------|------------------------------|
| | <i>2013 n = 254</i> | <i>2014 n = 357</i> | <i>2014 n = 737</i> | <i>2015 n = 497</i> | |
| <i>NNRTI mutations</i> | | | | | |
| L100I | 0 | 0 | 0.4 | 0.2 | 0.2 |
| K101EP | 0.8 | 0.3 | 1.1 | 0.6 | 0.8 |
| K103NS | 6.3 | 6.2 | 9.2 | 6.6 | 7.5 |
| V106AM | 0.8 | 0.8 | 2.0 | 1.0 | 1.4 |
| Y181C | 0.4 | 0 | 0.1 | 0.6 | 0.3 |
| Y188LC | 0.4 | 0 | 0.3 | 0.6 | 0.3 |
| G190AS | 0 | 0.8 | 0.7 | 0.2 | 0.5 |
| P225H | 1.2 | 0.8 | 1.1 | 0.8 | 1.0 |
| M230L | 0 | 0.3 | 0.4 | 0.2 | 0.3 |
| Overall NNRTI resistance | 7.5 | 7.6 | 11.9 | 9.7 | 9.9 |
| <i>NRTI mutations</i> | <i>n = 254</i> | <i>n = 357</i> | <i>n = 737</i> | <i>n = 497</i> | <i>n = 1,845</i> |
| M41L | 0 | 0.3 | 0.3 | 0.2 | 0.2 |
| K65R | 1.2 | 0.3 | 0.7 | 0.4 | 0.6 |
| D67N | 0.8 | 0 | 0.1 | 0.4 | 0.3 |
| T69D | 0 | 0.3 | 0 | 0 | 0.1 |
| K70R | 0.8 | 0 | 0 | 0.4 | 0.2 |
| K70E | 0.0 | 0.3 | 0.0 | 0.6 | 0.2 |
| L74VI | 0.4 | 0.3 | 0.1 | 0.2 | 0.2 |
| Y115F | 0 | 0 | 0.3 | 0.2 | 0.2 |
| M184VI | 3.1 | 2.0 | 2.6 | 2.0 | 2.4 |
| L210W | 0 | 0 | 0.1 | 0 | 0.1 |
| T215DEV | 0.4 | 0 | 0.1 | 0 | 0.1 |
| T215Y | 0.4 | 0 | 0 | 0 | 0.1 |
| K219ENR | 0.8 | 0.6 | 0.3 | 0.2 | 0.4 |
| Overall NRTI resistance | 4.7 | 3.4 | 3.1 | 2.4 | 3.2 |
| <i>PI mutations^a</i> | <i>n = 254</i> | <i>n = 356</i> | <i>n = 736</i> | <i>n = 495</i> | <i>n = 1,841</i> |
| L24I | 0 | 0 | 0 | 0.2 | 0.1 |
| M46IL | 0.4 | 0.6 | 0.7 | 2.0 | 1.0 |
| F53Y | 0 | 0 | 0 | 0.2 | 0.1 |
| I54V | 0.4 | 0.3 | 0 | 0 | 0.1 |
| L76V | 0.4 | 0.3 | 0 | 0 | 0.1 |
| V82A | 0.4 | 0.3 | 0 | 0 | 0.1 |
| I85V | 0 | 0.3 | 0 | 0.4 | 0.2 |
| L90M | 0.8 | 0 | 0 | 0 | 0.1 |
| Overall PI resistance | 0.8 | 0.8 | 0.7 | 2.6 | 1.2 |

All figures are percentages; figures in *bold* are levels of resistance $\geq 5\%$. The following surveillance drug resistance mutations were not detected in either study and are therefore not listed: L23I, D30N, V32I, I47VA, G48VM, I50LV, G73STCA, N83D, I84VAC, N88DS, T69ins, V75MTAS, F77L, F116Y, Q151M, and V179F.

^aDenominator for PI mutations based on number of complete *PR* sequences.

NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.

improvement within the HIV treatment program, particularly with respect to adherence support, routine virologic monitoring, and timely ART switching.^{44,45}

Overall, around 1 in 10 participants had at least one NNRTI SDRM, the most frequent mutation being K103NS, which is consistent with the national PDR survey,¹⁵ and is the most common NNRTI mutation documented in the context of ADR on first-line ART.⁴⁷ The persistence of this mutation in the absence of drug pressure⁴⁸ may increase the chance of onward transmission, and the levels documented here raise concern about the continued effectiveness of efavirenz (EFV) and nevirapine in first-line regimens. The levels of NRTI

resistance were relatively low, and the estimated prevalence of key SDRMs associated with TDF resistance (K65R and K70E) was below 1% in both studies. This was also consistent with the national survey that estimated the prevalence of K65R at 1.4%.¹⁵ At the time of these studies, TDF had still only been in widespread use in first-line ART regimens for under 5 years, so continued vigilance is required, especially as high levels of K65R have been documented in those with ADR on first-line ART, and with evidence supporting the transmissibility of K65R variants.^{47,49} However, these findings provide reassurance for now about the place of TDF in first-line ART and PrEP regimens.⁵⁰ Although the levels of

PI resistance were low, the two instances of multiple major PI mutations and triple class resistance raise some concern. The information available from the public sector health records suggested that neither had been exposed to ART. However, multiple major PI mutations and triple class resistance suggest that the two individuals had prior use of ART. Therefore, these findings should be interpreted with caution, given the potential for data linkage problems, access to ART in a public sector program outside the study area, or access to ART in the private sector.

From the phylogenetic analysis, ~15% of the individuals with SDRM from study A and B were linked in a transmission cluster with at least one other person with an identical SDRM. Fourteen of 32 ART-naïve individuals were linked with ART-experienced individuals whose sequences were in the background dataset. In these linkages, we can infer that drug-resistance mutations were most likely transmitted from ART-experienced individuals to ART-naïve individuals in the same cluster. For the other 18 ART-naïve individuals with PDR, the source of drug resistance is most likely to be from ART-experienced individuals that were not part of our study sample, although we cannot exclude onward transmission from ART-naïve individuals and undisclosed ART exposure. K103N was the most common mutation observed in the linked cases, consistent with a study from Aruba, a highly HIV endemic area in the Caribbean.⁵¹ However, unlike the Aruba cluster, where onward transmission of K103N was observed among ART-naïve individuals in a large transmission chain, the pattern of small and independent transmission clusters observed here is more suggestive of multiple transmission events from people with ADR on ART.

Our findings suggest that additional public health interventions may now be required in South Africa, as recommended by the WHO.^{2,3} One option would be to introduce genotypic resistance testing before ART initiation, but this would have substantial cost implications and present considerable operational challenges. The more likely option would be to change the standard first-line ART regimen, probably to an integrase inhibitor-based regimen. Dolutegravir (DTG) has already replaced EFV in first-line ART in neighboring Botswana, and there are plans for it to be introduced for first-line ART in South Africa in 2019.^{11,52} While there are some concerns about introducing DTG in the South African context (e.g., with paucity of studies on the use of DTG in pregnancy and dosing in people with tuberculosis on rifampicin), cost savings are an additional driver to adopt this for first-line therapy.⁵²

Our findings should be interpreted with certain limitations, as the two studies were not conducted as formal drug resistance surveys for pretreatment or transmitted drug resistance. Although population-based studies present challenges in accurately determining current and prior ART use, they might have some advantages over facility-based HIVDR surveys in that they include a more broadly representative sample of HIV-positive people in the population, including people not accessing health care. However, this representativeness is diminished if there are low levels of consent in population-based surveys, as seen in the AHRI surveillance.⁵³ There was substantial attrition in the laboratory processes, particularly with the DBS specimens, and we cannot be certain that the participants whose virus was successfully sequenced were representative of all eligible ART-naïve people in the study populations. Our capacity to uncover linked drug resistant transmissions was

limited by the relatively low coverage of people living with HIV in the study areas, particularly for study B. Finally, as these studies were in geographically restricted populations, these results should not be taken to be representative of the entire province of KZN, or of South Africa more generally.

In conclusion, the high levels of PDR documented here highlight the need for renewed focus on improving the quality of HIV prevention, treatment, and care. In particular, the systems for routine VL monitoring for people on ART and switching to second-line ART should be strengthened. These findings should be interpreted together with results of the national drug resistance survey to inform the need for modification of the standard first-line ART regimen or the introduction of other public health measures to prevent the spread of drug resistance.

Acknowledgments

This work was supported by a flagship grant from the South African Medical Research Council (MRC-RFA-UFSP-01-2013/UKZN HIVEPI). The HIV Incidence Provincial Surveillance System is supported by the Presidents' Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of cooperative agreement 3U2GGH000372-02W1. CAPRISA was established as part of the Comprehensive International Program of Research on AIDS (CIPRA) and supported by the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH), and the U.S. Department of Health and Human Services (DHHS) (Grant 1U19 AI51794). Parts of this research were supported by the South African Medical Research Council and the DST-NRF Centre of Excellence in HIV Prevention, which is supported by the Department of Science and Technology and the National Research Foundation. The AHRI and its population-based HIV surveillance system are supported by core funding from the Wellcome Trust (grant nos. 097410/Z/11/Z and 201433/A/16/A, www.wellcome.ac.uk). A.B.M.K. is supported by the joint South Africa-U.S. Program for Collaborative Biomedical Research from the National Institutes of Health (R01HD083343). Our sincere thanks to all household members and individual study participants who through their participation have contributed immensely to the understanding of the HIV epidemic in this region. A special thanks to the study staff for the fieldwork and laboratory work. The authors sincerely acknowledge all the HIPSS co-investigators from the following organizations: Epicentre, CAPRISA, Health Economics and HIV and AIDS Research Division (HEARD), National Institute for Communicable Diseases (NICD), and CDC. The authors thank their collaborating partners for the HIPSS study: the National Department of Health; Provincial KZN Department of Health; uMgungundlovu Health District; the uMgungundlovu District AIDS Council; local, municipal, and traditional leaders, and community members. The authors also thank their partners for the AHRI population-based surveillance system: the Provincial KZN Department of Health; uMkhanyakude Health District; Hlabisa Health Sub-district; local, municipal, and traditional leaders, and community members. The authors also acknowledge support from Letten Foundation, Norway, and the National Health Laboratory Services, Department of Virology, at the UKZN.

Disclaimer

The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official position of the funding agencies.

Author Disclosure Statement

No competing financial interests exist.

References

- Hamers RL, Kityo C, Lange JMA, Wit TFR de, Mugenyi P: Global threat from drug resistant HIV in sub-Saharan Africa. *BMJ* 2012;344:e4159.
- World Health Organization: Global action plan on HIV drug resistance 2017–2021. Available at http://apps.who.int/iris/bitstream/10665/255883/1/97892415128_48-eng.pdf (2017), accessed September 3, 2017.
- World Health Organization: Guidelines on the public health response to pretreatment HIV drug resistance. Available at <http://apps.who.int/iris/bitstream/10665/255880/1/9789241550055-eng.pdf> (2017), accessed August 31, 2017.
- World Health Organisation: Surveillance of HIV drug resistance in adults initiating antiretroviral therapy (pretreatment HIV drug resistance). Available at http://apps.who.int/iris/bitstream/10665/112802/1/9789241507196_eng.pdf?ua=1 (2014), accessed March 13, 2017.
- World Health Organization: *The HIV Drug Resistance Report 2017*. Geneva: WHO. Available at http://apps.who.int/iris/bitstream/10665/255896/1/97892415128_31-eng.pdf, accessed September 3, 2017.
- Phillips AN, Stover J, Cambiano V, *et al.*: Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in sub-Saharan Africa. *J Infect Dis* 2017;215:1362–1365.
- Cambiano V, Bertagnolio S, Jordan MR, Lundgren JD, Phillips A: Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings. *J Infect Dis* 2013;207 (Suppl 2):S57–S62.
- Hamers RL, Schuurman R, Sigaloff KCE, *et al.*: Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: A multicentre cohort study. *Lancet Infect Dis* 2012;12:307–317.
- Wittkop L, Günthard HF, de Wolf F, *et al.*: Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study. *Lancet Infect Dis* 2011;11:363–371.
- World Health Organization: Guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Available at http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf (2015), accessed March 9, 2017.
- Health-e News: Landmark ARV pricing deal to save SA billions. Cape Town. Available at <https://www.health-e.org.za/2017/09/22/landmark-arv-pricing-deal-save-sar11-bn-six-years/> (2017), accessed September 22, 2017.
- Hunt GM, Ledwaba J, Basson AE, *et al.*: Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal provinces, South Africa, 2005–2009. *Clin Infect Dis* 2012;54 (Suppl 4):S334–S338.
- Parboosing R, Naidoo A, Gordon M, Taylor M, Vella V: Resistance to antiretroviral drugs in newly diagnosed, young treatment-naïve HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa. *J Med Virol* 2011;83:1508–1513.
- Manasa J, Danaviah S, Lessells R, *et al.*: Increasing HIV-1 drug resistance between 2010 and 2012 in adults participating in population-based HIV surveillance in rural KwaZulu-Natal, South Africa. *AIDS Res Hum Retroviruses* 2016;32:763–769.
- Steege K, Carmona S, Bronze M, *et al.*: Moderate levels of pre-treatment HIV-1 antiretroviral drug resistance detected in the first South African National survey. *PLoS One* 2016;11:e0166305.
- van Zyl GU, Grobbelaar CJ, Claassen M, Bock P, Preiser W: Moderate levels of pre-therapy drug resistance (PDR) in a generalised epidemic: Time for better first-line ART? *AIDS* 2017;13:2387–2391.
- Manasa J, Lessells RJ, Skingsley A, *et al.*: High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa. *PLoS One* 2013;8:e72152.
- Tanser F, Hosegood V, Bärnighausen T, *et al.*: Cohort profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. *Int J Epidemiol* 2008;37:956–962.
- Houlihan CF, Bland RM, Mutevedzi PC, *et al.*: Cohort profile: Hlabisa HIV treatment and care programme. *Int J Epidemiol* 2011;40:318–326.
- Kharsany ABM, Cawood C, Khanyile D, *et al.*: Strengthening HIV surveillance in the antiretroviral therapy era: Rationale and design of a longitudinal study to monitor HIV prevalence and incidence in the uMgungundlovu District, KwaZulu-Natal, South Africa. *BMC Public Health* 2015;15:1149.
- de Oliveira T, Kharsany ABM, Gräf T, *et al.*: Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: A community-wide phylogenetic study. *Lancet HIV* 2017;4:e41–e50.
- Grobler A, Cawood C, Khanyile D, Puren A, Kharsany ABM: Progress of UNAIDS 90-90-90 targets in a district in KwaZulu-Natal, South Africa, with high HIV burden, in the HIPSS study: A household-based complex multilevel community survey. *Lancet HIV* 2017;4:e505–e513.
- Kharsany ABM, Cawood C, Khanyile D, *et al.*: Community-based HIV prevalence in KwaZulu-Natal, South Africa: Results of a cross-sectional household survey. *Lancet HIV* 2018;5:e427–e437.
- Manasa J, Danaviah S, Pillay S, *et al.*: An affordable HIV-1 drug resistance monitoring method for resource limited settings. *J Vis Exp* 2014;85.
- Gifford RJ, Liu TF, Rhee SY, *et al.*: The calibrated population resistance tool: Standardized genotypic estimation of transmitted HIV-1 drug resistance. *Bioinformatics* 2009;25:1197–1198.
- Bennett DE, Camacho RJ, Otelea D, *et al.*: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. *PLoS One* 2009;4:e4724.
- Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira T; Southern Africa Treatment And Resistance Network (SATuRN): Primary drug resistance in South Africa: Data from 10 years of surveys. *AIDS Res Hum Retroviruses* 2012;28:558–565.
- Shafer RW, Rhee SY, Pillay D, *et al.*: HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. *AIDS* 2007;21:215–223.

29. Price MN, Dehal PS, Arkin AP: FastTree 2 – Approximately maximum-likelihood trees for large alignments. *PLoS One* 2010;5:e9490.
30. Ragonnet-Cronin M, Hodcroft E, Hué S, *et al.*: Automated analysis of phylogenetic clusters. *BMC Bioinformatics* 2013;14:317.
31. Gupta RK, Gregson J, Parkin N, *et al.*: HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. *Lancet Infect Dis* 2018;18:346–355.
32. Rhee SY, Blanco JL, Jordan MR, *et al.*: Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: An individual-patient and sequence-level meta-analysis. *PLoS Med* 2015;12:e1001810.
33. Haber N, Tanser F, Bor J, *et al.*: From HIV infection to therapeutic response: A population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa. *Lancet HIV* 2017;4:e223–e230.
34. Parkin N, de Mendoza C, Schuurman R, *et al.*: Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network. *Clin Infect Dis* 2012;54 (Suppl 4):S273–S279.
35. Harrison L, Castro H, Cane P, *et al.*: The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. *AIDS* 2010;24:1917–1922.
36. Poon AFY, Aldous JL, Mathews WC, *et al.*: Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: Prevalence and effects on pre-therapy CD4 and viral load. *PLoS One* 2011;6:e21189.
37. Manne-Goebler J, Rohr J, Montana L, *et al.*: ART Denial: results of a home-based study to validate self-reported antiretroviral use in rural South Africa. *AIDS Behav* 2018 Dec 6. [Epub ahead of print] DOI: 10.1007/s10461-018-2351-7.
38. Kim AA, Mukui I, Young PW, *et al.*: Undisclosed HIV infection and antiretroviral therapy use in the Kenya AIDS indicator survey 2012: Relevance to national targets for HIV diagnosis and treatment. *AIDS* 2016;30:2685–2695.
39. Silverman RA, Beck IA, Kiptinness C, *et al.*: Prevalence of pre-antiretroviral treatment drug resistance by gender, age, and other factors in HIV-infected individuals initiating therapy in Kenya, 2013–2014. *J Infect Dis* 2017;216:1569–1578.
40. Bor J, Herbst AJ, Newell ML, Bärnighausen T: Increases in adult life expectancy in rural South Africa: Valuing the scale-up of HIV treatment. *Science* 2013;339:961–965.
41. Bor J, Rosen S, Chimbini N, *et al.*: Mass HIV treatment and sex disparities in life expectancy: Demographic surveillance in rural South Africa. *PLoS Med* 2015;12: e1001905; discussion e1001905.
42. National Department of Health: (South Africa). Joint review of HIV, TB and PMTCT programmes in South Africa. Available at <https://www.health-e.org.za/wp-content/uploads/2014/04/who-final-report-of-joint-hiv-tb-pmtct-main-report.pdf> (2014), accessed May 2, 2017.
43. Médecins sans Frontières: Getting to 90-90-90 what will it take? Perspectives and realities from the field. Available at http://www.msf.org/sites/msf.org/files/getting_to_90-90-90_what_will_it_take.pdf (2016), accessed January 16, 2017.
44. Venter WD, Ford N, Vitoria M, Stevens W: Diagnosis and monitoring of HIV programmes to support treatment initiation and follow up and improve programme quality. *Curr Opin HIV AIDS* 2017;12:117–122.
45. Murphy RA, Court R, Maartens G, Sunpath H: Second-line antiretroviral therapy in sub-Saharan Africa: It is time to mind the gaps. *AIDS Res Hum Retroviruses* 2017;33:1181–1184.
46. Winand R, Theys K, Eusébio M, *et al.*: Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naïve individuals. *AIDS* 2015;29:2045–2052.
47. Steegen K, Bronze M, Papathanasopoulos MA, *et al.*: HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: Results from a national survey in South Africa. *J Antimicrob Chemother* 2017;72:210–219.
48. Pingen M, Wensing AMJ, Fransen K, *et al.*: Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity. *Retrovirology* 2014;11:105.
49. The TenoRes Study Group: Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study. *Lancet Infect Dis* 2016;16:565–575.
50. Bekker LG, Rebe K, Venter F, *et al.*: Southern African guidelines for the safe use of pre-exposure prophylaxis in men who have sex with men who are at risk for HIV infection. *South Afr J HIV Med* 2016;17:455.
51. Hofstra LM, Sánchez Rivas E, Nijhuis M, *et al.*: High rates of transmission of drug-resistant HIV in Aruba resulting in reduced susceptibility to the WHO recommended first-line regimen in nearly half of newly diagnosed HIV-infected patients. *Clin Infect Dis* 2017;64:1092–1097.
52. Venter WDF, Kaiser B, Pillay Y, *et al.*: Cutting the cost of South African antiretroviral therapy using newer, safer drugs. *S Afr Med J* 2017;107:28–30.
53. Larmarange J, Mossong J, Bärnighausen T, Newell ML: Participation dynamics in population-based longitudinal HIV surveillance in rural South Africa. *PLoS One* 2015;10: e0123345.

Address correspondence to:

Benjamin Chimukangara
 KwaZulu-Natal Research Innovation and Sequencing
 Platform (KRISP)
 School of Laboratory Medicine and Medical Sciences
 University of KwaZulu-Natal
 719 Umbilo Road
 Durban 4001
 South Africa

E-mail: benjiechim@yahoo.com